Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced a collaboration agreement with Visikol® for service offerings using Imaging Mass Cytometry™. SOUTH SAN FRANCISCO, Calif.
The microfluidics-based system accommodates scalable throughputs to address specific and evolving project needs SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human
SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of August 22, 2022 , under the
Second quarter revenue of $18.8 million Completed $250 million strategic cash infusion from Casdin Capital and Viking Global Upgraded management team and added board members to bring significant sector and operational expertise to the company Commenced restructuring program with the explicit
SOUTH SAN FRANCISCO, Calif. , July 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after
SOUTH SAN FRANCISCO, Calif. , May 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced financial results for the first quarter ended March 31, 2022 . “The end of first quarter
SOUTH SAN FRANCISCO, Calif. , April 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after
Capacity to Process 100-Plus Samples per Week, with 1.6x Lower Limit of Detection SOUTH SAN FRANCISCO, Calif. , April 11, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced the
SOUTH SAN FRANCISCO, Calif. , April 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (f/k/a Fluidigm Corporation) (Nasdaq:FLDM) today announced, as required by Nasdaq Stock Market Rules, the grant of equity inducement awards to its new executive officers Michael Egholm , the Company’s new
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif.
